openPR Logo
Press release

Global Oncolytic Virus Therapy Pipeline Analysis

06-30-2017 12:21 PM CET | Health & Medicine

Press release from: PNS Pharma

Though still in nascent stages, Oncolytic viruses have shown immense opportunities and potential to be tapped in the future to improve the treatment of cancer and the lives of the patients. Immunotherapy, the umbrella for Oncolytic viruses would not offer cures, but survival solutions with significant importance. Also, the side effects of this therapy would be tolerable by the patients, which could thus become the most important approach to treat cancer by 2020.

The form of Oncolytic virus, which has the maximum potential in the future and is the most promising, is the reovirus. This is a non-enveloped virus with a double-stranded, segmented RNA genome which forms particles of 60 to 90 nm size. The reovirus duplicates in those cancer cells which have a common mutation called “activated Ras pathway”. The normal cells are not impacted. Thus the virus is made intrinsically tumor selective without the need for any genetic manipulation.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Global-Oncolytic-Virus-Therapy-Pipeline-Analysis

“Global Oncolytic Virus Therapy Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various Oncolytic virus drugs being developed for the treatment of multiple cancers. Research report covers all the ongoing Oncolytic Virus drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Oncolytic Virus market based upon development process.

Following parameters for each Oncolytic Virus drug profile in development phase are covered in research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes

Oncolytic Virus Drug by Clinical Phase:

• Research: 1

• Preclinical: 16

• Phase-I: 6

• Phase-I/II: 5

• Phase-II: 5

• Phase-III: 2

• Registered: 1

• Discontinued: 16

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Oncolytic Virus Therapy Pipeline Analysis here

News-ID: 603627 • Views: 519

More Releases from PNS Pharma

Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight: o Global Gene Therapy Market Opportunity: > US$ 8 Billion o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials o Commercially Available Gene Therapies: 11 o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials o Cancer Accounts For 50% of Global Gene Therapy Trials Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026 Over the years, gene therapy has been highly responsible for decreasing the mortality rate
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria

All 5 Releases


More Releases for Oncolytic

Creative Biolabs Upgrades Oncolytic Virus Product List for Immunotherapy Researc …
As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and kill tumor cells. Up to now, two OV drugs have been
Oncolytic Virus Therapy Industry – Treatment Analysis,Research,Review to 2025
WiseGuyReports.Com Publish a New Market Research Report On –“ Oncolytic Virus Therapy Industry – Treatment Analysis,Research,Review to 2025”. Description: This report studies the Oncolytic Virus Therapy market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Oncolytic Virus Therapy market by product type and applications/end industries. Oncolytic Virus Therapy is
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Oncolytic Virus 1.1 Outline of Oncolytic Virotherapy 1.2 Trail from Genesis to Biogenetics Primer of Virotherapy in Malignancies 2.1 Oncolytic Viruses towards Cancer 2.2 Approaches for Targeting Tumor Cells 2.2.1 Pro Apoptotic Targeting 2.2.2 Translational Targeting 2.2.3 Transcriptional Targeting 2.2.4 Transductional Targeting Mechanism
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic
Global Oncolytic Virus Therapy Market & Oncolytic Virus clinical Trials Outlook …
Advancements in human genomics over the last two decades have shown that cancer is mediated by somatic aberration in the host genome. This discovery has incited enthusiasm among cancer researchers; many now use therapeutic approaches in genetic manipulation to improve cancer regression and find a potential cure for the disease. The dominant cancer treatment modalities such as chemotherapy, radiotherapy, and even targeted kinase inhibitors and mAbs are limited by low
Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic